Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

ARSYNL Rx vs GoodRx

ARSYNL Rx
Graded #348

Lower grade

vs+10.499999999999993
GoodRx
Graded #122

Higher grade

The verdict

GoodRx takes it — 69.6/100 to 59.1/100.

GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGoodRx +37
43
80
Dose & formulationGoodRx +6
64
70
Clinical oversightARSYNL Rx +9
78
69
Labs & monitoringARSYNL Rx +2
53
51
FulfillmentGoodRx +18
63
81
Contract termsEven
55
55
ARSYNL Rx · left barGoodRx · right bar

The numbers

MetricARSYNL RxGoodRx
WeighScore59.1/10069.6/100
GradeCC
Scorecard rank#348#122
Semaglutide$233/mo (compounded)Not disclosed
Tirzepatide$366/mo (compounded)$299/mo (brand Zepbound)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
ARSYNL Rx

Graded #348 · C

Strengths

  • Offers compounded semaglutide and tirzepatide, including a needle-free tirzepatide hypospray option
  • Veteran-founded telehealth with clinician-prescribed, personalized treatment
  • Multi-service platform — also covers hair restoration, TRT, sexual health, and longevity
  • Medications shipped discreetly to your home

Where it loses points

  • Pricing is not shown until you select a product (product pages sit behind a bot-verification gate)
  • Compounded GLP-1s are not FDA-approved finished products
  • Compounding pharmacy partner and exact state coverage are not disclosed on the site
  • No LegitScript certification visible on the accessible pages
GoodRx

Graded #122 · C

Strengths

  • $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
  • $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
  • Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
  • No membership fee — bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded

Where it loses points

  • Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
  • Self-pay only — does not apply toward insurance benefits or deductibles
  • Headline price applies to the lowest Foundayo dose; higher doses may cost more
  • No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
  • Pricing can change as Lilly's manufacturer coupon program evolves

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard